Navigation Links
Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
Date:12/1/2009

INDIANAPOLIS and NORTH VANCOUVER, British Columbia, Dec. 1 /PRNewswire-FirstCall/ -- Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), and Agrisoma Biosciences, Inc. today announced the signing of a research and commercial license option agreement. The agreement provides Dow AgroSciences with access to Agrisoma's proprietary Engineered Trait Loci (ETL) technology on an exclusive basis in major food crops, and on a non-exclusive basis, in other crop species.

Dow AgroSciences and Agrisoma have collaborated since 2004 in the area of high value protein production in plants and plant cell cultures. The initial collaboration formed the foundation of a successful relationship. This new agreement builds on that relationship and expands use of the ETL technology into field crops.

"Dow AgroSciences' strategic investment in Agrisoma's ETL technology will accelerate the creation of new and novel products in crop plants, such as increased levels and improved forms of healthier oils or other beneficial food components," said Dan Kittle, Ph.D., Dow AgroSciences vice president for R&D. "ETL technology will be an important tool in our 'toolbox' to deliver differentiated solutions enabled by the expression of multiple genes or enhancements in complex biochemical pathways."

Agrisoma's ETL technology is a patent protected, broadly applicable technology that facilitates the placement of new traits in the native genome of a crop. The ETL technology has been used to engineer oil composition, oil content and yield for the renewable energy market and ETL-engineered crops are now undergoing a second year of field trials at multiple locations.

"We recognize Dow AgroSciences as a premiere global leader in plant biotechnology and are tremendously excited about the opportunity to expand our collaboration with Dow AgroSciences," said Steven Fabijanski, Agrisoma's president and chief executive officer. "Agrisoma has demonstrated the utility, stability and performance our ETL technology in a broad range of crops, including important food crops such as soybeans and canola. Our ETL technology has proven performance, and through this new collaboration with Dow AgroSciences, we hope to be able to commercialize this technology in major global food crops. The research collaboration with Dow AgroSciences complements our industrial crop program which is focused on creating renewable feedstocks using dedicated bioenergy plants."

About Agrisoma Biosciences

Agrisoma Biosciences Inc. is a private agricultural biotechnology company using its leading edge ETL technology to create new crop varieties engineered for high value applications such as biofuel production and renewable manufacturing feedstock. Agrisoma's ETL, or Engineered Trait Loci technology allows efficient stacking and expression of multiple traits in any crop species. For further information about Agrisoma, and its technology, collaborations and partnerships, please visit: www.agrisoma.com

About Dow AgroSciences LLC

Dow AgroSciences LLC, based in Indianapolis, Indiana, USA, is a top-tier agricultural company that combines the power of science and technology with the "Human Element" to constantly improve what is essential to human progress. Dow AgroSciences provides innovative technologies for crop protection, pest and vegetation management, seeds, traits, and agricultural biotechnology to serve the world's growing population. Global sales for Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), are $4.5 billion. Learn more at www.dowagro.com.

Note: Certain of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

SOURCE Dow AgroSciences


'/>"/>
SOURCE Dow AgroSciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dow AgroSciences, Monsanto Complete U.S. and Canadian Regulatory Authorizations for SmartStax Corn; Plans Set to Launch Seed Platform on 3 Million- to 4 Million-Plus Acres
2. Dow AgroSciences, NemGenix Establish New Collaboration in Plant Biotechnology
3. Dow AgroSciences, China National Rice Research Institute Announce Collaboration on Rice Research
4. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
5. Dow AgroSciences, Martek Biosciences Form Alliance to Bring Omega-3 Fatty Acids to Food Industry
6. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration
7. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
8. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
9. American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
10. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
11. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
Breaking Biology Technology:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):